Core Insights - The event focuses on the aryl hydrocarbon receptor and the EQ504 program, which targets immune-mediated disorders, particularly ulcerative colitis [2][3] Company Overview - Equillium Bio is presenting its EQ504 program aimed at treating ulcerative colitis, highlighting the high unmet medical need despite significant investments in existing therapies [3] Expert Involvement - The event features Dr. Francisco Quintana and Dr. Brian Feagan, who are specialists in immune-mediated disorders and gastroenterology, respectively, emphasizing the importance of their expertise in discussing the drug target [3]